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Abstract
Cultured splenic stroma has been shown to support in vitro hematopoiesis in overlaid bone
marrow and spleen progenitors. These co-cultures support longterm production of a novel
dendritic-like cell type along with transient production of myeloid cells. They also maintain a
progenitor cell population. The splenic stromal lines 5G3 and 3B5 have been identified as a
supporter and a non-supporter of hematopoiesis. Based on their gene expression profile,
both 5G3 and 3B5 express genes related to hematopoiesis, while 5G3 cells express several
unique genes, and show upregulation of some genes over 3B5. Based on gene expression
studies, specific inhibitors were tested for capacity to inhibit hematopoiesis in co-cultures.
Addition of specific antibodies and small molecule inhibitors identified VCAM1, CXCL12,
CSF1 and SPP1 as potential regulators of hematopoiesis, although both are expressed by
5G3 and 3B5. Through inhibition of function, SVEP1 and ALDH1 are also shown here to be
deterministic of 5G3 hematopoietic support capacity, since these are uniquely expressed by
5G3 and not 3B5. The achievement of inhibition is notable given the dynamic, longterm
nature of co-cultures which involve only small numbers of cells. The alternate plan, to add
recombinant soluble factors produced by 5G3 back into 3B5 co-cultures in order to recover
in vitro hematopoiesis, proved ineffective. Out of 6 different factors added to 3B5, only IGF2
showed any effect on cell production. The identification of differentially expressed or upregu-
lated genes in 5G3 has provided an insight into potential pathways involved in in vitro hema-
topoiesis leading to production of dendritic-like cells.
Introduction
Multiple dendritic cell (DC) subsets are present in spleen under steady-state and inflammatory
conditions. DC precursors continually seed spleen from bone marrow where they develop into
the well characterised cDC and pDC subsets [1]. Here we investigate splenic stromal lines
which support in vitro hematopoiesis to produce novel dendritic-like cells following co-culture
with hematopoietic progenitors from bone marrow or spleen [2–4]. The main subset of den-
dritic-like cells produced have been characterised for their distinct phenotype and functional
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capacity [5–7], and in vivo equivalent subsets have been identified in both mouse [8, 9] and
human [10]. Mutant mouse studies have identified their progenitor origin as spleen rather
than bone marrow. This novel subset is still produced in c-MybE308G mutant mice where devel-
opment of bone marrow-derived dendritic and myeloid cells is compromised [11].
The importance of splenic stromal cells in hematopoiesis was first demonstrated for spleen-
derived long-term cultures (LTC) which continually support myelopoiesis for years [12, 13].
The spleen stromal cell microenvironment maintains progenitor cells and supports restricted
differentiation [14, 15]. Subsequent studies involved the heterogeneous spleen stromal cell line
STX3 [12, 16] derived from one LTC that had ceased production of hematopoietic cells. Gene
profiling of STX3 compared with the 2RL22 lymph node stroma, led to description of STX3 as
an immature mesenchymal cell type which did not express mature endothelial cell markers
but weakly formed tube-like structures in Matrigel [16, 17]. The STX3 stromal cell line was
cloned to give multiple cell lines [18] which were each characterised in terms of morphology
and ability to support DC hematopoiesis in vitro. This study identified the cloned stromal line
5G3 as a supporter of hematopoiesis, and 3B5 as a non-supporter. 5G3 has been characterised
in detail in terms of its hematopoietic support capacity [2, 6, 19, 20].
Here, the 5G3 supporter and the 3B5 non-supporter lines have been compared through tran-
scriptome analysis to identify of differences in gene expression to determine genes that may be
critical determinants of in vitro hematopoiesis. Identification of differentially expressed or upregu-
lated genes is a powerful approach for detecting novel genes and novel molecular pathways indica-
tive of specific functional potential. Several genes have been identified which encode potential
hematopoietic regulators. Their importance in hematopoiesis has been tested through application
of available inhibitors to co-cultures to determine importance for hematopoietic output.
Materials and methods
Animals
Specific pathogen-free C57BL/6J (H-2Kb) mice aged 6 weeks were obtained from the John
Curtin School of Medical Research (JCSMR: Canberra, ACT, Australia). Mice were housed
and handled according to protocols approved by the Animal Experimentation Ethics Commit-
tee at the Australian National University (ANU: Canberra, ACT, Australia).
Cell culture
The continuous stromal cell lines 5G3 and 3B5 have been previously described [21, 22]. They
were cloned from an original STX3 splenic stroma [13, 23, 24], established from a longterm cul-
ture (LTC) of B10.A(2R) mouse spleen which had ceased production of DC over time due to
loss of hematopoietic cells. Stroma was maintained by scraping cells for passage into a new flask
and culture at 37˚C in 5% CO2 in air in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum, 5 x 10-4M 2-mercaptoethanol, 10mM HEPES, 100U/ml peni-
cillin, 100ug/ml streptomycin, 4mg/L glucose, 6mg/L folic acid, 36mg/L L-asparagine, 116mg/L
L-asparagine hydrochloric acid (sDMEM). These were frozen down within 4–5 passages of
cloning, and stromal lines passaged only 4–5 times after thawing for use in experiments.
Isolation of bone marrow progenitors
Mice were killed by cervical dislocation. Bone marrow was obtained from femurs and tibias by
flushing cells from the bone cavity using a syringe filled with sDMEM. Bone marrow suspen-
sions were dissociated by forcing tissue through a fine wire sieve. In preparation for antibody-
mediated magnetic cell depletion, cells were washed twice with 10ml labelling buffer [degassed
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PBS pH7.2, 0.5% bovine serum albumin and 2mM EDTA] by centrifugation at 300g and 4˚C
for 10 minutes. A cell pellet was resuspended in 40μl of labelling buffer containing a cocktail of
biotin-labelled antibodies specific for hematopoietic lineage markers CD5, CD45R, CD11b,
Gr-1 (Ly-6G/C), 7–4, and Ter-119 (10μl per 107 cells) (Lineage depletion kit, Miltenyi Biotec:
North Ryde, NSW, Australia) to which was added antibody to the DC marker CD11c (BioLe-
gend: San Diego, CA, USA), for 10 minutes on ice. Following this, 30μl of labelling buffer and
20μl of MACS1 anti-biotin microbeads (Miltenyi Biotec) were added to cells and incubated
on ice for a further 15 minutes. Cells were washed with 2ml of labelling buffer followed by cen-
trifugation at 300g and 4˚C for 10 minutes. Cells were resuspended in 500μl of labelling buffer
and transferred to a MACS1MS column (Miltenyi Biotec) and placed in a SuperMACS1 II
Separator (Miltenyi Biotec). Cells which bind biotinylated antibody and the MACS1 anti-bio-
tin microbeads are retained in the column. The MACS1MS column was then washed three
times with 500μl of labelling buffer and flow through cells collected. Cells were washed twice
with sDMEM by centrifugation at 300g and 4˚C for 5 minutes. An aliquot of the lineage
depleted (Lin-) cell population was tested for the presence of lineage positive cells by antibody
staining and flow cytometric analysis.
Stromal cell co-cultures
The capacity of stromal cells to support hematopoiesis was assessed by overlay of Lin- bone
marrow cells above stromal cell monolayers grown to 80–90% confluency followed by co-cul-
ture for several weeks. Lin- bone marrow cells were plated at 1–5 x 104 cells/ml above the stro-
mal monolayer in 25cm2 flasks. Co-cultures were held at 37˚C, 5% CO2 in air and 97%
humidity. At 7-day intervals, non-adherent cells were collected by gently shaking the flask
with removal and replacement of supernatant. Cell yield was determined by counting using
Trypan blue exclusion staining and cells analysed for surface marker expression by antibody
staining and flow cytometric analysis. Specific inhibitors or growth factors were added into
some co-cultures using a concentration range recommended by the supplier. These are listed
in Tables 1 and 2. Additives were replenished at biweekly medium change.
Microscopy
The morphology of stromal cells was monitored microscopically before and after addition of
overlay cells. Cultures of stroma alone, or cocultures of Lin- bone marrow cells above stroma
were photographed using a DM IRE2 inverted research microscope (Leica: North Ryde, NSW,
Australia) equipped with DFC digital camera (Leica) to obtain phase contrast photomicro-
graphs. Images were processed using Leica IM software v4.0.
Table 1. Recombinant factors added to 3B5 co-cultures.
Recombinant factor (Supplier) Factor specificity
SFRP2 (R&D Systems) Homologue of Frizzled; acts as a modulator of WNT signalling
RSPO2 (R&D Systems) Activator for WNT/β-catenin signalling
IGF2 (R&D Systems) Growth factor that binds to IGF1
POSTN (R&D Systems) An adhesion molecule and tumour suppressor
WNT5a (R&D Systems) Member of the non-canonical WNT pathway
CCL8a (Biolegend) Chemokine that acts as an antagonist of CCR8
�Biolegend (San Diego, CA, USA); R&D Systems (Minneapolis, MN, USA).
https://doi.org/10.1371/journal.pone.0205583.t001
Regulation of in vitro hematopoiesis
PLOS ONE | https://doi.org/10.1371/journal.pone.0205583 October 11, 2018 3 / 20
Flow cytometry
For analysis of cell surface marker expression and subsequent subset delineation, cells were
stained with antibodies diluted in fluorescence-activated cell sorting (FACS) buffer (DMEM/0.1%
sodium azide/1% fetal calf serum). Antibody specific for FcγII/IIIR (CD32/CD16) (eBiosciences:
San Diego, CA, USA) was used at 5 μg/106 cells in 1ml to block non-specific antibody binding.
Fluorochrome or biotin-conjugated antibodies for CD11b (M1/70), CD11c (N418), MHC-II
(AF6-120.1), CD45RB (C363.16A), Sca-1 (D7), c-Kit 2B8), streptavidin-PE-Cy7, streptavidin-PE,
streptavidin-FITC and isotype control antibodies were purchased from either Biolegend or eBios-
ciences (San Diego, CA, USA). All antibodies were titrated to determine concentration giving
minimal saturating binding. Cells labelled with fluorochrome-conjugated antibodies were ana-
lysed in both multicolour and single colour staining protocols. Discrimination of live cells utilized
staining with 1μg/ml propidium iodide (PI) (Sigma-Aldrich: Castle Hill, NSW, Australia). Isotype
matched control antibodies or fluorescence minus one (FMO) controls were used to set gates to
delineate specific antibody binding. Flow cytometric analysis was carried out using BD FACSDiva
(Becton Dickinson) and FlowJo software (Tree Star: Ashland, OR, USA).
Specific antibodies used in inhibition studies were titrated before use in co-cultures through
binding to control Lin- bone marrow cells, at concentrations of 0.3, 1 and 3 μg/mL. These are
listed in Table 2. Median fluorescence intensity (MFI) was calculated as the net change in
median channel fluorescence for specific antibody above isotype controls. Anti-CD11a, anti-
CD44 and anti-CD49d antibodies bound strongly to target molecules on Lin- bone marrow
cells, giving shifts in median fluorescence intensity between 300 and 13000. Anti-CXCR7 and
anti-ITGA9 bound to only small numbers of cells amongst Lin- bone marrow cells and so were
titrated on hematopoietic stem cells (HSC) sorted from Lin- bone marrow as the Lin- Sca-1+c-
Kit+ subset.
Transcriptome analysis
Total RNA was isolated from stromal cell lines, and concentration and purity determined spectro-
photometrically. Double stranded cDNA was synthesized from RNA in a two-step process. The
first strand of cDNA was synthesis using T7-(dT)24 primers and Superscript II reverse transcrip-
tase (Invitrogen Life Technologies: Mount Waverley, VIC, Australia). This was followed by sec-
ond strand cDNA synthesis. Double-stranded DNA was then purified using phenol-chloroform
together with phase-lock gels (Brinkmann Instruments: Westbury, NY, USA). In vitro transcrip-
tion and biotin labelling were performed using the BioArray High Yield RNA Transcript
Table 2. Inhibitors tested in 5G3 co-cultures.
Inhibitor (Supplier)� Inhibitor Activity
DEAB (Stem Cell Technologies) ALDH1 expressed by 5G3 and HSPC
GW2580 (Biovision
Incorporated)
CSFR1, receptor for CSF1 produced by stroma
Anti-CXCR7 Mab (Biolegend) CXCR7 on HSPC, receptor for CXCL12 produced by stroma
Anti- ITGA9 serum
(LifeSpan BioSciences)
ITGA9 on HSPC, ligand for SVEP1 expressed by 5G3, and SPP1/TNC expressed
by stroma
Anti-CD11a Mab (Biolegend) CD11a on HSPC, ligand for CLCA1 expressed by 5G3
Anti-CD44 Mab (Biolegend) CD44 on HSPC, receptor for SPP1/TNC expressed by 5G3
Anti-CD49d Mab (Biolegend) CD49d on HSPC, ligand for VCAM1/FN expressed by stroma
�Biolegend (San Diego, CA, USA); Biovision Incorporated (Milipitas, CA, USA); Lifespan Biosciences (Seattle, WA,
USA); Stem Cell Technologies (Vancouver, BC, CA).
https://doi.org/10.1371/journal.pone.0205583.t002
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Labelling Kit (Affymetrix: Santa Clara, CA, USA). cRNA was purified on RNeasy Spin columns
(Qiagen, SABiosciences: Valencia, CA, USA), fragmented, and labelled with biotin. Labelled
cRNA was then hybridized to Murine Genome 430v2 genechips (Affymetrix) following the man-
ufacturer’s instructions. They were washed followed by staining on the fluidics station (Affyme-
trix), ahead of scanning and image analysis using a Gene Array Scanner (Affymetrix). Scanned
images of genechips were processed using Microarray Suite 5.0 software (MAS5.0; Affymetrix).
Data files were prepared in Microsoft Excel containing probeset numbers, signal values and p-val-
ues. Further analysis involved extraction of data according to set criteria. The preparation of label,
hybridisation to genechips, scanning, data compilation and basic analysis was performed by staff
in the Biomolecular Resources Facility (JCSMR: Canberra, ACT, Australia).
Real-time polymerase chain reaction
Total RNA was isolated from stromal cell lines using the RNeasy mini kit following the manu-
facturer’s protocol (Qiagen). RNA was purified using the genomic DNA elimination mix, and
concentration and purity determined spectrophotometrically. Following this, Buffer BC3,
Control P2, Reverse Transcriptase mix and RNase-free water were added in ratios of 4:1:2:3
for preparation of cDNA. Incubation proceeded for 15 mins at 42˚C for denaturation, then for
5 mins at 95˚C to convert RNA into cDNA. Subsequently, cDNA was diluted in RNase-free-
water for use in Realtime PCR reactions. Equal volumes of cDNA and primer (10μM stock)
were mixed. Primers were purchased from SABioscience (Frederick, MD 21703, USA).
These included: Abcg1 (PPM03895A); Actb (PPM02945A); Aldh1 (PPM04398F); Apod
(PPM05327F); Ccl8 (PPM03165A); Clca1 (PPM04051E); Csf1 (PPM03116C); Ctla2a
(PPM27745A); Cxcl12 (PPM02965E); Igf2 (PPM03655A); KitL (PPM02983C); Ms4a4d
(PPM24757A); Postn (PPM34333E); Rspo2 (PPM32746A); Serpinα3n (PPM05779F); Sfrp2
(PPM03616C); Spp1 (PPM03648C), Svep1 (PPM05259A); Wnt5a (PPM04748C). The cDNA/
primer mixture was then added to RT2 SYBR Green Mastermix and RNase-free water in a
ratio of 1:6.25:5.25, respectively. Samples were loaded on to a LightCycler 480 (Roche: Castle
Hill, NSW, Australia). The cycling conditions used were: 1 cycle for 10 mins at 95˚C to activate
DNA Taq Polymerase, followed by 45 cycles of 15 sec at 95˚C for extension, and then 1 min at
60˚C for fluorescence data collection.
Data analysis involved LightCycler 480 software v.1.2.9.11. (Roche). The Absolute Quantifi-
cation (2nd derivative max) method was used to obtain a cross point value (Cp), referred to as
the cycle threshold (Ct). Cp is the point of maximal increase in fluorescence emitted by a single
PCR reaction within the log-linear phase. To further analyse data, Ct values for genes of inter-
est (GOI) along with housekeeping genes (HKG) were imported into Excel (Microsoft: Red-
mond, WA, USA). ΔCt = Ct (GOI)–Ct (HKG) was calculated, and the average ΔCt taken from
quadruplicate experiments. To calculate the fold change between two samples, the calculation
2-ΔCt (Sample 1) / 2-ΔCt (Sample 2), was used. The resulting value corresponds to the relative
difference in mRNA quantity between two samples. The presence of an amplified product was
confirmed by gel electrophoresis.
Statistical tests
When replicates were available, data are presented as mean ± standard error (SE) for sample
size n. The Wilcoxon Rank Sum test has been routinely used to test significance (p�0.05).
In experiments involving addition of inhibitors (or replacement factors) where very small
numbers of progenitor cells were available, a titration of additives was performed in preference
to replication of tests of additive at just one concentration. A significant inhibitory (or
enhancement) effect was indicated by the outcome of even or decreasing (increasing) cell
Regulation of in vitro hematopoiesis
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production over 4 dilutions of additive. The null hypothesis is that cell production is random
across the titration, and the alternative hypothesis is that decreasing (or increasing) cell pro-
duction occurs with increasing concentration of additive. The probability of an ordered reduc-
ing (or expanding) sequence for cell production over four different dilutions is 1/24 or 0.0417
which is significant at p�0.05.
Results
Differential support of hematopoiesis by splenic stroma
Photomicrographs showed that 5G3 stroma displayed cobblestone morphology, while 3B5
stroma was more elongated and displayed a spindle-shaped fibroblastic morphology (Fig 1A).
3B5 and 5G3 have different capacity to support myelopoiesis in overlaid Lin- bone marrow
progenitors. Large non-adherent cells were detectable at 7 and 14 days above 5G3 but not
above 3B5 (Fig 1A). Cocultures of only Lin- bone marrow cells showed no viable cells after 14
days (not shown). Cell yield (%) determined by Trypan blue exclusion of recovered non-
adherent cells at 7 and 14 days showed that 5G3 produced a significantly higher yield of live
cells relative to input cell number than did 3B5 (Fig 1B). 3B5 co-cultures were only weakly able
Fig 1. Comparison of splenic stromal lines for support of hematopoiesis. Co-cultures were established by overlay of Lin- bone marrow cells on 3B5 and 5G3
stroma in 3 replicate experiments involving the same starting cell number. ‘Stroma only’ and ‘Lin- bone marrow only’ cultures (not shown) served as controls. (A)
Co-cultures were photographed at 7 and 14 days under phase contrast microscopy (Objective 20x, bar 100μm). (B) Non-adherent cells were collected after 7 and 14
days, and live cell recovery (% yield) estimated on the basis of input cell number. Data are presented as mean ± standard error (n = 3). Percent yield from 3B5 co-
cultures is statistically different from 5G3 co-cultures, and control cultures of only Lin- bone marrow at both 7 and 14 days (p�0.05). (C) Non-adherent cells collected
at 7 and 14 days were analysed flow cytometrically after gating live (PI-) cells. The phenotype of cells gated on forward and side scatter (FSC, SSC) was determined
using antibody staining to detect expression of CD11c, CD11b, MHC-II and CD45RB. Isotype control antibodies were used to detect non-specific binding shown as a
red overlay, and to set cross-hairs on bivariate antibody plots. Numbers in quadrants represent % positive cells.
https://doi.org/10.1371/journal.pone.0205583.g001
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to support hematopoiesis in vitro, and less than 20% of input cells was recovered after 14 days.
No live cells were recovered from ‘stroma only’ control cultures (Fig 1B).
Flow cytometry was used to distinguish live cells produced in co-cultures and to analyse
their cell surface phenotype. Non-adherent cells produced in Lin- bone marrow co-cultures
were collected at 7 and 14 days and stained with antibodies for CD11c, CD11b, MHC-II and
CD45RB. Ahead of flow cytometry, cells were stained with PI to identify live (PI-) cells. After
gating to remove debris on a forward scatter (FSC) versus side scatter (SSC) plot, DC were
identified as CD11b+CD11c+ and myeloid cells as CD11b+CD11c-. MHC-II and CD45RB
were used to identify mature and any regulatory DC amongst CD11c+ cells, respectively (Fig
1D). CD11b+CD11c+MHC-II+ cells produced are phenotypically similar to CD8α- cDC [25],
while CD11b+CD11c+MHC-II- cells resemble immature DC produced in splenic LTC and
were termed L-DC [26]. From as early as 7 days, the cell yield in 5G3 co-cultures was notice-
ably higher than in 3B5 co-cultures. While the proportional distribution of subsets was similar
for both stroma at 7 days, by 14 days 5G3 co-cultures produced 57% CD11b+CD11c+ myeloid
DC compared with 3B5 co-cultures which produced only 9%. Also, 5G3 co-cultures produced
a higher percentage of L-DC (CD11b+CD11c+MHC-II-) (24%), compared with 3B5 co-cul-
tures (4%). This showed 5G3 to be the best supporter, and 3B5, a weak or non-supporter of
myelopoiesis. These co-cultures produced few CD11b+CD11c+CD45RB+ cells, described by
others as regulatory DC [27].
Identification of specific and upregulated genes in 5G3
Transcriptome analysis was performed to identify genes specifically expressed or upregulated
in 5G3 stroma compared with 3B5, to identify specific regulators of in vitro hematopoiesis.
Affymetrix Murine Genome 430v2.0 genechips were employed and duplicate experiments
conducted. Several hypotheses were investigated. Firstly that supporting stroma like 5G3
express genes which encode molecules important for cell-contact dependent signalling leading
to hematopoietic differentiation. The second was that 5G3 secretes cytokines or chemokines
which specifically support hematopoiesis. Comparative analysis across two experiments
involved normalisation of genechips and removal of variation due to batch effect.
Specific criteria were established to identify differentially expressed genes (Fig 2). A p-value
of�0.04 was set to detect genes expressed by 5G3, and a p-value of>0.06 to detect genes not
expressed by 3B5. The signal value threshold was set at�50. Datasets were obtained for each
of two experiments and selection of genes across both experiments gave a dataset of 20 genes.
Table 3 lists these genes and their signal values for 5G3 expression. Apod, Svep1, Plxdc2, Aldh1,
Serpina3n and Abcg1 were selected, on the basis of high signal value and potential role in
hematopoiesis, for verification of differential gene expression using Realtime PCR (Fig 3). This
confirmed that these 6 genes were expressed in significantly higher levels in 5G3 above 3B5.
Criteria imposed to select genes upregulated in 5G3 over 3B5 are described in Fig 2. This
analysis selected genes present in both 5G3 and 3B5 as defined by the detection call in the
MAS5.0 software. Fold change was calculated as the ratio of 5G3 over 3B5 signal values.
Eighty-eight genes with an average fold change of�4.0 were identified. Genes were then
grouped into functional categories using Gene Ontology, and functional categories relevant to
hematopoiesis were identified. Categories selected included transcriptional regulation, signal-
ling molecules, receptors, matrix remodelling, immunity and inflammation, extracellular
matrix/cell adhesion, development and cytokines/chemokines. This gave 56 genes of interest
(Fig 4). Several genes with a potential role in hematopoiesis were then selected for further
quantification using Realtime PCR. These included: Ms4a4d, Clca1, Plxdc2, Postn, Rspo2,
Sfrp2, Ctla2α, Igf2 and Ccl8 (Fig 3).
Regulation of in vitro hematopoiesis
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Affymetrix profiling indicated the common expression by both 5G3 and 3B5 of several
genes which encode known regulators of hematopoiesis, including Cxcl12, Csf1, KitL, Spp1,
Vcam1 and Wnt5a, and Realtime PCR was used to confirm gene expression (Fig 3). Since
these genes were all commonly expressed by 5G3 and 3B5 stroma, they are not considered to
be deterministic of hematopoiesis in this in vitro system. However, expression of Cxcl12, KitL
and Spp1, but not Csf1 or Wnt5a, was significantly higher in 5G3 than in 3B5.
Growth factors as regulators of in vitro hematopoiesis
Genes of interest either upregulated or specifically expressed by 5G3 over 3B5 included soluble
factors available as commercially recombinant molecules in highly purified form (Table 1).
The possibility was tested that addition of these to 3B5 co-cultures of Lin- bone marrow cells
over 3B5 may restore hematopoietic support capacity. This experiment was conducted bearing
in mind the possibility that one factor alone may not be sufficient to restore hematopoietic
support function to 3B5. Lin- bone marrow progenitors were overlaid on 3B5 stroma, and co-
cultures maintained for 14 days. Every 4 days, co-cultures were supplemented with recombi-
nant factors at concentrations of 0, 0.03, 0.1 and 0.3 μg/mL. Cell counting and flow cytometric
Fig 2. Procedure for identification of gene expression in stromal lines. Transcriptome analysis of 5G3 and 3B5 stroma
employed Affymetrix Murine Genome 430v2 genechips. Two separate experiments were performed and data normalised
for comparison of replicate samples. MAS5.0 (Affymetrix) software was used to standardize genechips and to calculate a
signal value and p-value statistic for all probe sets. Gene annotation and literature searches were performed to identify
genes of interest and to make predictions about gene function.
https://doi.org/10.1371/journal.pone.0205583.g002
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analysis was used to quantitate cells produced in co-cultures. As in Fig 1, myeloid cells are
identified as CD11b+CD11c- and DC as CD11b+CD11c+ cells. Progenitors cells would be pres-
ent within the CD11b-CD11c- fraction. In these experiments it was very difficult to isolate suf-
ficient cell numbers to do many replicates within the one experiment. Therefore, a titration of
additives was used, such that a significant inhibitory (or enhancing) effect was determined by
the outcome of decreasing cell (or increasing) production over 4 dilutions of added factor.
While 5G3 co-cultures produce a high yield of cells with a predominance of DC, 3B5 pro-
duce at least 10-fold fewer cells with a predominance of myeloid cells (Fig 5A and 5B). Addi-
tion of SFRP2, RSPO2, POSTN and CCL8a had minimal effect on cell production and no
noticeable effect on the relative proportion of cells produced in 3B5 co-cultures. None of these
factors alone was able to restore the high cell production typical of 5G3. While IGF2 and
WNT5a are known regulators of hematopoiesis, addition to 3B5 failed to increase cell yield in
co-cultures. However, IGF2 addition produced a significant concentration-dependent increase
in the CD11b-CD11c- fraction containing progenitors with a reduction in myeloid cell produc-
tion (Fig 5B). This suggests a distinct role for IGF2 in the proliferation of progenitors, consis-
tent with previous reports for its role in stem cell proliferation [28–30]. While IGF2 addition
failed to restore cell production to 5G3 levels, it did impact the hematopoietic events underway
in 3B5. Several experiments also involved addition of all factors in combination used at the
same concentration as individually. This gave no change in the production of cells compared
with unsupplemented co-cultures.
Table 3. Identification of genes specifically expressed in 5G3 but not 3B5.
Probe set Gene Symbol Gene Title Signal value�
Expt 1 Expt 2
1416371_at Apod apolipoprotein D 1694.3 1327.6
1419182_at Svep1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 1206.7 758.3
1419100_at Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 821.9 821.9
1451440_at Chodl chondrolectin 577.2 116.1
1418912_at Plxdc2 plexin domain containing 2 298.3 280.0
1426758_s_at Meg3�� maternally expressed 3 283.8 243.3
1416468_at Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 277.8 591.1
1435261_at Tmtc1 transmembrane and tetratricopeptide repeat containing 1 206.8 156.0
1418672_at Akr1c13 aldo-keto reductase family 1, member C13 177.3 218.0
1417577_at Trpc3 transient receptor potential cation channel, subfamily C, member 3 168.4 169.6
1424032_at Hvcn1 hydrogen voltage-gated channel 1 166.1 282.6
1418603_at Avpr1a�� arginine vasopressin receptor 1A 161.4 235.1
1450243_a_at Rcan2 regulator of calcineurin 2 128.0 135.4
1423570_at Abcg1 ATP-binding cassette, sub-family G (WHITE), member 1 111.5 96.0
1423266_at Fam123b family with sequence similarity 123, member B 93.0 88.0
1453317_a_at Khdrbs3 KH domain containing, RNA binding, signal transduction associated 3 80.6 132.8
1436736_x_at Nrep�� neuronal regeneration-related protein 79.3 78.4
1451716_at Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) 73.2 95.1
1450492_at Cngb3 cyclic nucleotide gated channel beta 3 70.2 52.4
1429444_at Rasl11a RAS-like, family 11, member A 48.9 114.5
�Gene expression reflects signal value (MAS5.0 calculation) in 5G3 (p� 0.04, signal value� 50) for genes where signal is absent for 3B5
(p > 0.06). Two independent experiments were performed. Genes listed in order of expression level for Expt 1.
��For these genes, two probe sets returned similar results, but only one representative probeset is shown.
https://doi.org/10.1371/journal.pone.0205583.t003
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Fig 3. Quantitation of gene expression differences. Realtime PCR was performed across two separate experiments (A
and B) to measure expression of selected genes determined by transcriptome analysis as upregulated or specifically
expressed in 5G3 over 3B5. Also in (A), several genes related to hematopoiesis were shown to be expressed by both 5G3
and 3B5. These included Cxcl12, Csf1, KitL, Spp1 and Wnt5a. Gene expression was quantified in terms of fold change
Regulation of in vitro hematopoiesis
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Specific regulators of hematopoiesis
Based on specific and upregulated gene expression by 5G3, several available reagents were
tested as inhibitors of hematopoiesis supported by 5G3 stroma. Some of these reagents have
unique binding specificity for adhesion molecules and growth factors specifically expressed by
5G3 but not 3B5. Others are less specific in their binding to the molecules of interest. The
inhibitors tested and their target molecules are listed in Table 2. Co-cultures were established
using Lin- bone marrow overlaid on 5G3 stroma. With the difficulty of isolating progenitors,
we chose to assess inhibition of cell production across a range of inhibitor concentrations such
that significant effects could be established as a dilution across a 4 point titration. All inhibitors
were specific for cell surface molecules. However, CXCR7 was shown to be expressed mainly
as an intracellular molecule, although its function could be inhibited by addition of antibodies
to culture medium [31]. Inhibitors added to co-cultures were replenished every 4 days at
medium change. Two independent experiments were conducted to test 7 different inhibitors.
DEAB is a specific inhibitor of aldehyde dehydrogenase including both ALDH1A1 and
ALDH2 [32], although only ALDH1A1 was found to be specifically expressed by 5G3 with
both 5G3 and 3B5 expressing ALDH2 (S1 Table). However, when used here as an inhibitor of
5G3 co-cultures, Diethylaminobezaldehyde (DEAB) produced a significant concentration-
dependent reduction in cell production, coincident with reduction in number of myeloid and
dendritic cells produced (Fig 6A). In order to determine whether SVEP1, expressed uniquely
by 5G3 and not 3B5, is deterministic of hematopoiesis in co-cultures, antibody specific for
ITGA9 was added into co-cultures. Integrin α9β1 expressed by HSC is a known binding recep-
tor for SVEP1 [33, 34]. A significant concentration-dependent reduction in cell production
was detected (Fig 6A), suggesting that this interaction is critical despite the fact that Integrin
α9β1 also binds to other molecules including FN, SPP1, ADAMs and TNC [35]. Affymetrix
data mining has shown that transcripts for both of these molecules are expressed by 5G3 and
3B5 (S1 Table). CLCA1 is uniquely expressed by 5G3 and not 3B5. Inhibition of function tests
in involved antibody to the CLCA1 ligand CD11a [36]. However CD11a also binds to several
other molecules including ICAMs and JAM-A [37, 38], although these were not found to be
expressed by 5G3 or 3B5 stroma (S1 Table). Since this antibody had little effect on cell produc-
tion in co-cultures, CLCA1 would not appear to be a candidate regulator of hematopoiesis (Fig
6B).
Further inhibition assays involved genes of interest due to their previously described roles
in regulating hematopoiesis. These included Cxcl12, Vcam1, Csf1 and Spp1 and were all shown
to be expressed by both 5G3 and 3B5 (S1 Table). CXCL12 is produced by stroma is known to
bind to both CXCR4 and CXCR7 expressed by HSC [39]. Evidence that antibody to CXCR7
inhibited cell production in co-cultures supports a potential role for CXCL12 in in vitro hema-
topoiesis (Fig 6A). Since CD49d is a ligand for VCAM1 expressed by 5G3, antibody to CD49d
was tested as an inhibitor (Fig 6A). Strong inhibition would suggest an important role for this
adhesive interaction in hematopoiesis in vitro. A role for CSF1 was tested through addition of
the GW2580 inhibitor of CSF1R to co-cultures. This reduced cell production in a concentra-
tion-dependent manner (Fig 6B), suggesting a requirement for CSF1. While a three point inhi-
bition test was not significant, this result is supported by evidence for a role for CSF1 in
myelopoiesis in spleen co-cultures identified previously [40]. SPP1(osteopontin) is a known
regulator of hematopoiesis in bone marrow which binds to CD44 [41]. When antibodies to
(mean ± SE; n = 2) relative to of Actb (β-actin), a control housekeeping gene. Expression of genes by 5G3 was
significantly different to 3B5 (p�0.05) for all genes except Csf1 andWnt5a.
https://doi.org/10.1371/journal.pone.0205583.g003
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Fig 4. Genes upregulated in 5G3 over 3B5. Data represent average fold change in gene expression for 5G3 over 3B5 shown as
mean ± S.E (n = 2). For the two most highly upregulated genes identified by �, SE is not shown but reflects 30–40% of the mean.
Genes were annotated using the Gene Ontology ‘molecular function’ tool and only genes in categories associated with the role of
stroma in hematopoiesis were selected.
https://doi.org/10.1371/journal.pone.0205583.g004
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CD44 were added into co-cultures, a four point dilution in cell production indicated signifi-
cant inhibition (Fig 6B). CD44 however also binds to several other molecules including hyal-
uronic acid and selectins, but there was no evidence from gene profiling that these genes were
expressed by 5G3 stroma, and so were unlikely targets for antibody inhibition.
Fig 5. Addition of growth factors to co-cultures established over 3B5. Lin- bone marrow was overlaid on 3B5
stroma and cultured in the presence and absence of recombinant factors. SFRP2, RSPO2, IGF2, WNT5a, CXCL12 and
CCL8 (Table 1) were added to cultures at 0, 0.03, 0.1 and 0.3 μg/mL. Every 4 days, a half volume of culture medium
was replaced with complete medium containing factors. Two separate experiments were performed (A and B). Non-
adherent cells were collected on Day 14 and stained with fluorochrome-conjugated antibodies specific for CD11b,
CD11c, MHC-II, and F4/80. Propidium iodide (PI: 1 μg/mL) staining was used to gate PI- live cells. ‘Fluorescence
minus one’ controls were used to set gates to identify specific antibody binding. Myeloid cells were gated as
CD11b+CD11c- cells, DC as CD11b+CD11c+ cells, and CD11b-CD11c- cells were gated as the fraction enriched for
progenitors. MHC-II expression was used to confirm identify of subsets (not shown). Data are presented as total
number of each cell type produced in co-cultures. No statistically significant enhancement of growth was identified
across a 4-point titration assay for any growth factor tested.
https://doi.org/10.1371/journal.pone.0205583.g005
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Discussion
The selection of differentially expressed genes involved stringent criteria for expression in 5G3
and not 3B5. The aim was to identify genes with high certainty of differential expression. The
selected genes in Table 3 represent a range of biological functions. These dictate functions of
transport (Abcg1, Apod, Cngb3 and Hvcn1), metabolism (Akr1c13), signalling (Avpr1a, Rcan2
Fig 6. Assessment of potential inhibitors of hematopoiesis. Co-cultures were established by overlay of 2.104 Lin-
bone marrow cells on 5G3 stroma in the presence and absence of inhibitors. Every 4 days, a half volume of medium
was replaced with medium containing inhibitor. Two experiments (A and B) were performed. Inhibitors included
DEAB, GW2580, and antibodies to CXCR7, CD11a, CD44, SPP1 and CD49d as listed in Table 2. Control (Con) co-
cultures contained no inhibitor or an isotype control antibody used at the highest antibody concentration for antibody.
Non-adherent cells were collected on Day 14 and stained with fluorochrome-conjugated antibodies specific for
CD11b, CD11c, MHC-II and F4/80. Propidium iodide (PI: 1 μg/mL) staining was used to gate PI- live cells.
‘Fluorescence minus one’ controls were used to set gates to identify specific antibody binding. Myeloid cells were gated
as CD11b+CD11c- cells, DC as CD11b+CD11c+ cells, and CD11b-CD11c- cells were gated as the fraction enriched for
progenitors. MHC-II expression was used to confirm identify of these subsets (not shown). Data are presented as total
number of each cell type produced in co-cultures. Statistically significant inhibition (p�0.05) was identified through a
consistent dilution effect across a 4-point titration and is shown as ��.
https://doi.org/10.1371/journal.pone.0205583.g006
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and Rasl11a), cell adhesion (Svep1), and development (Serpina3n, Plxdc2, Meg3, Aldh1a1 and
Nrep). Genes which dictate development or cell-cell contact are of primary interest, particu-
larly those expressed in highest levels like Apod, Svep1, and Serpina3n and the proteins
encoded by Plxdc2 and Aldh1a1. The dominant expression of many of these genes in 5G3 over
3B5 was confirmed by Realtime PCR (Fig 3). The function of ALDH1a1 and SVEP1 in in vitro
hematopoiesis is predicted through studies showing that specific inhibitors DEAB (for
ALDH1a1) and anti-ITGA9 (for SVEP1) inhibited cell production in 5G3 co-cultures (Fig 6).
Precedence also exists in the literature for the involvement of SVEP1, SERPINa3n, and
ALDH1a1 in HSC differentiation in vivo. Evidence for their involvement in the production of
L-DC in stromal co-cultures is also consistent with previous evidence that HSC are direct pro-
genitors of L-DC in vitro [11, 20, 42]. SVEP1 is of interest because of its novelty, and its
involvement in cell adhesion [43]. Only recently it was shown that SVEP1 binds to ITGA9, a
member of the integrin family of molecules which regulate cell adhesion, migration and signal-
ling [44]. A study by Schreiber et al. [34] showed that anti-ITGA9 antibodies absorbed to
HSPC led to a 60% reduction in their adhesion to osteoblasts. Antibodies to integrin α9 also
inhibited cell proliferation and differentiation in cytokine-supplemented cultures of HSPC.
Addition of anti-ITGA9 antibody to 5G3 co-cultures studied here gave an overall reduction in
cell production. SVEP1 may contribute to the adhesion of HSPC to stroma which is essential
for myelopoiesis. SERPINa3n and SERPINa3g were found to be specifically expressed or upre-
gulated by 5G3 stroma. SERPINa3 has previously been identified as an important regulator of
HSC maintenance [45]. There are 14 replicates of SERPINa3 (a-n) in the mouse chromosome
which function as protease inhibitors that control serine peptidases through cleavage and inac-
tivation of molecules which retain HSC in the microenvironment, so influencing HSC mobili-
zation [45]. ALDH1a1 is an enzyme that drives retinoic acid synthesis [46], and the retinoic
acid signalling pathway has been shown to drive both LT-HSC and ST-HSC proliferation [47].
The importance of ALDH1a1 expressed by 5G3 stroma in HSC proliferation is indicated
through inhibition with DEAB leading to a reduction in cell production.
The selection of upregulated genes involved criteria that genes be expressed in both 5G3
and 3B5, with an average fold change across two experiments of�4-fold. This protocol
selected genes within functional categories related to the hematopoietic support capacity of
stroma. Genes most highly upregulated, included Hoxa10, Ms4a4d, Clca1, Plxdc2, Spon1,
Postn, Rspo2, Sfrp2, Ctla2, Igf2 and Ccl8. These genes should provide the molecular interac-
tions between stroma and HSC necessary for maintenance of HSC in the quiescent state, HSC
self-renewal, and cell fate decisions leading to proliferation, signalling for stem cell migration,
and further differentiation.
Adhesion molecules are of particular interest in terms of regulation of hematopoiesis in
stromal co-cultures. CLCA1 binds to LFA-1, an adhesion molecule expressed on HSC [48].
While CLCA1 is highly upregulated in 5G3 stroma, and is also expressed on lymphatic endo-
thelial cells in spleen [49], we were unable to demonstrate a functional role in hematopoiesis in
vitro. In terms of regulators of early hematopoiesis, secreted proteins RSPO2 and SFRP2 are
known regulators of Wnt signalling, particularly involving WNT3a, which is central to HSC
self-renewal [50]. They bind to WNT3a with opposite outcomes. RSPO2 amplifies WNT3a sig-
nalling, promoting HSC maintenance and self-renewal [51], while SFRP2 negatively regulates
WNT3a [52, 53], so stimulating HSC proliferation [54]. Dynamic interaction between these
two proteins may be key to switching HSC between self-renewal and proliferation. These mol-
ecules may play an important role in in vitro hematopoiesis since they are highly upregulated
in 5G3 over 3B5 stroma. However, addition to 3B5 co-cultures was insufficient to trigger
hematopoiesis, possibly since important adhesion molecules were also not expressed by 3B5.
Another soluble factor, chemokine CCL8, was found to be upregulated in 5G3 over 3B5. CCL8
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cooperation with CXCL12 is known to attract hematopoietic progenitors with a potential to
differentiate into regulatory DC [55]. The role of CXCL12 in HSC maintenance is well docu-
mented [56], and both 5G3 and 3B5 express high levels. Hence, interaction between these two
chemokines, in the context of hematopoiesis supported by 5G3 stroma, indicates potential for
production of regulatory DC in stromal co-cultures. Recent work from this lab has identified
transient production of regulatory DC in co-cultures, but clearly distinguishes them from
L-DC which are continuously produced [57].
This report also establishes the expression and importance of genes which are known regu-
lators of hematopoiesis and the production of myeloid cells in 5G3 stromal co-cultures. CSF1
is a known regulator of myelopoiesis from in vivo studies in mice. The injection of CSF1 into
C57BL/6 mice promotes DC development from common myeloid progenitors with a resultant
2-fold increase in splenic pDC and cDC numbers [58]. Previous studies in this lab revealed an
important role for CSF1 in the development of cDC-like cells, but not L-DC, in co-cultures of
Lin- bone marrow over 5G3 stroma [20, 40]. The CSF1R inhibitor, GW2850, had a strong
inhibitory effect on the production of myeloid cells. It is possible therefore that CSF1 produced
by 5G3 acts as a growth factor to promote myeloid cell development, and cDC-like cell pro-
duction in Lin- bone marrow co-cultures.
Antibody to CD44 was also a very effective inhibitor of cell production in co-cultures. The
target of inhibition appears to be specifically L-DC. This suggests that SPP1 (osteopontin), a
ligand for CD44 expressed by 5G3, may play a fundamental role in L-DC development. SPP1
is known to maintain HSC in the quiescent state by promoting engraftment to the stem cell
niche [59, 60]. SPP1 expressed by 5G3 may act to regulate and maintain progenitors in co-cul-
tures, such that when SPP1 function is inhibited with antibody, more progenitors differentiate,
and their numbers become exhausted. This would lead to a reduction in the differentiation of
cells, and particularly L-DC production which are known to arise by direct differentiation
from HSC and MPP [20, 40].
Several known regulators of in vivo hematopoiesis have been identified in this study.
CXCL12 binds to CXCR4 and CXCR7 which are receptors on HSPC [41]. While CXCR7 was
not shown to be expressed as a cell surface receptor on HSC in this study, it must be expressed
transiently, since anti-CXCR7 antibodies gave a noticeable reduction in cell production. The
importance of VCAM1 expressed by 5G3 was demonstrated through anti-CD49d inhibition of
cell production in co-cultures. The CD49d-VCAM1 interaction promotes cell adhesion, and
so VCAM1 on 5G3 may be important for adhesion of progenitors to stroma where it acts as
a regulator of proliferation and differentiation. This finding is supported by evidence that
stem cell mobilising agents applied to Vcam1-/- mutant mice gave an increase in circulating
CFU-C over wild type mice, with a decrease in CFU-C accumulation in bone marrow and
spleen [61].
Several other molecules identified reflect potential regulators of in vitro hematopoiesis.
CTLA2 is expressed highly in the trabecular bone region of the bone marrow, suggesting a
potential role in hematopoiesis [62]. PLXDC2, is unknown in its role in hematopoiesis, but is
well-documented as a mitogen that drives neural stem cell proliferation [63]. These molecules
together with MS4A4D are relatively unexplored in the context of hematopoiesis, but their
upregulation in 5G3 over 3B5 makes them interesting targets for further study.
Conclusion
The cloned stromal cell line 5G3 is a supporter of hematopoiesis while 3B5 is a non-supporter.
5G3 supports production of dendritic-like cells as well as myeloid cells and progenitors, while
3B5 transiently supports the production of only low numbers of myeloid cells. Gene expression
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profiling was performed using Affymetrix genechips to compare gene expression between 5G3
and 3B5 stroma and to identify genes which regulate this process. Initially, data mining identi-
fied gene expression essential for hematopoiesis in bone marrow including Cxcl12, KitL, Spp1,
Vcam1 and Csf1. Hematopoiesis is responsible for the production of myeloid cells, and this is
supported by evidence that antibodies or inhibitors of several of these gene products which act
through blocking receptors (anti-CXCR7 for CXCL12; anti-CD49 for VCAM1; and GW2580
for CSF1R) led to reduced cell production of in 5G3 co-cultures. Such evidence justifies the
search for differentially expressed or upregulated genes in 5G3 over 3B5 as determinants of in
vitro hematopoiesis, and verifies the model co-culture system as highly suitable for returning
genes which determine the hematopoietic support environment of HSC.
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